Results 151 to 160 of about 77,084 (260)

Gliomas with pleomorphic and pseudopapillary features (GPAP) are circumscribed tumors with targetable mutations, prolonged survival, and frequent tumor predisposition

Brain Pathology, EarlyView.
DNA methylation profiling identifies GPAP as a distinct circumscribed glioma with a characteristic expansive, multicystic radiological appearance, pleomorphic and pseudopapillary histology, a recognizable CNV profile, druggable molecular alterations, and recurrent cancer predisposition syndromes.
Alberto Picca, Valeria Barresi, Aude Trinquet, Luca Bertero, Lucia Nichelli, Guillaume Chotard, Michèle Bernier, Thomas Gareau, Salah Eddine Oussama Kacimi, Jaydutt Bhalshankar, Mathilde Filser, Julien Masliah‐Planchon, Marta Iollo, Henri Malaize, Bertrand Mathon, Luc Bauchet, Kifah Khouri, Besma Barka, Hélène Madry, Sabrina Rossi, Evelina Miele, Giuseppe Kenneth Ricciardi, Catherine Carpentier, Irina Coin, Marc Sanson, Mehdi Touat, Caroline Dehais, Alessia Pellerino, Roberta Rudà, Paola Cassoni, Valérie Rigau, Emmanuelle Uro‐Coste, Karima Mokhtari, Ahmed Idbaih, Patrick R. Benusiglio, Franck Bielle   +35 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

sGC stimulator BAY 41‐8543 improves survival and ventricular function in a rat model of doxorubicin‐induced cardiomyopathy with nephrotic syndrome

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline‐induced cardiomyopathy.
Olga Gawrys, Petra Škaroupková, Soňa Kikerlová, Zdeňka Vaňourková, Martina Hüttl, Olga Lenčová, Kasin Yadunandam Anandam, Svenja Stomberg, Sönke Behrends, Barbara Szeiffová Bačová, Matúš Sykora, Lisa Dietz, Peter Sandner, Luděk Červenka, Martin Štěrba   +14 more
wiley   +1 more source

Germline homologous recombination deficiency influences TP53-mutant clonal hematopoiesis fitness during platinum and PARP inhibitor treatment. [PDF]

Nat Genet
Baeten JT, Chan ICC, Moukarzel L, Petrone GEM, Liu J, Tran D, Tabs J, Tabet I, Agashe S, Nasrollahzadeh E, Vasireddy A, Carter A, Patel M, Stopsack KH, Kantoff PW, Zhou W, Batchi-Bouyou AL, Beeler JS, Mustion G, Pharoah P, Brenton J, Offit K, Barnett E, Li B, Abida W, Schram AM, Weigelt B, Mutch D, Vindigni A, Mullen M, Cruchaga C, Scher H, Levine R, Papaemmanuil E, Machiela MJ, Cadoo K, Link DC, Bolton KL.   +37 more
europepmc   +1 more source

PARP inhibitors synergize with abiraterone [PDF]

Nature Reviews Clinical Oncology, 2018
openaire   +2 more sources

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

Case Report: Personalized therapy in gynecological neuroendocrine neoplasm: a case of BRCA2-mutated ovarian neuroendocrine carcinoma treated with PARP-inhibitor. [PDF]

Front Oncol
Mantiero M, Polignano M, Bassetti A, Oldani S, Serino R, Russo A, Villa C, Ducceschi M, Raspagliesi F.   +8 more
europepmc   +1 more source

Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small‐Cell Lung Cancer Models

Cancer Science, EarlyView.
Dietary NA restriction converts the effect of NAMPT inhibition from cytostatic to cytotoxic in SCLC in vivo. ABSTRACT Small‐cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. We previously showed that nicotinic acid riboside (NAR) sustains NAD biosynthesis in vivo and compensates for NAMPT inhibition in SCLC models ...
Kyoji Tsurumi, Miyuki Nomura, Mai Ouchi, Shigehiro Yagishita, Naohiko Kikuchi, Taku Sato, Mami Morita, Yoji Yamashita, Kayoko Hayashi, Tomoyoshi Soga, Akinobu Hamada, Tatsuro Fukuhara, Nobuhiro Tanuma   +12 more
wiley   +1 more source

A transcriptomic-based model associated with PARP inhibitor sensitivity and immunogenic signatures in ovarian cancer. [PDF]

Discov Oncol
Sun X, Li C, Wang Z, Geng J, Wang W, Deng K, Xu Z, Zhao H, Huang D.   +8 more
europepmc   +1 more source

Decreased Expression by a Chemically Modified siRNA to PTBP1 Seriously Affects Warburg Effect in Colorectal Cancer Cells

Cancer Science, EarlyView.
Chemically modified siR‐PTBP1 disrupts the Warburg effect by reprogramming pyruvate kinase splicing from PKM2 to PKM1. This metabolic shift activates the TCA cycle, increases ATP production, and excessive ROS generation, and ultimately induces apoptotic cell death in colorectal cancer cells.
Keita Matsumoto, Hirokatsu Hayashi, Yoshihisa Tokumaru, Seito Fujibayashi, Noriki Mitsui, Masahide Endo, Takeshi Horaguchi, Yuji Hatanaka, Ryoma Yokoi, Chika Mizutani, Masashi Kuno, Masahiro Fukada, Ryuichi Asai, Itaru Yasufuku, Yuta Sato, Jesse Yu Tajima, Yoshihiro Tanaka, Remi Nakashima, Yukihiro Akao, Nobuhisa Matsuhashi   +19 more
wiley   +1 more source